Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
JACKSONVILLE, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Regency Centers Corporation (“Regency,” “Regency Centers,” or the “Company”) (Nasdaq: REG) announced today that its operating partnership,...
-
SINGAPORE, Feb. 18, 2026 (GLOBE NEWSWIRE) -- RF Acquisition Corp III (the “Company”) today announced that it closed its initial public offering of up to 10,000,000 units at a price of $10.00 per...
-
–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE)...
-
Minnesotta, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Learning Care Group opened the doors today to two new Everbrook Academy locations in Minnesota, serving the families of the newly developed communities...
-
CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage immuno-oncology company developing next-generation...
-
RICHMOND, Va., Feb. 17, 2026 (GLOBE NEWSWIRE) -- ARKO Corp. (Nasdaq: ARKO) (“ARKO”) and ARKO Petroleum Corp. (Nasdaq: APC) (“APC”), today announced the closing on February 13, 2026 of APC’s initial...
-
NORWALK, Ct, Feb. 13, 2026 (GLOBE NEWSWIRE) -- HCM IV Acquisition Corp. (Nasdaq: HACQU) (the “Company”), a blank check company whose business purpose is to effect a merger, amalgamation, share...
-
SINGAPORE, Feb. 12, 2026 (GLOBE NEWSWIRE) -- RF Acquisition Corp III (the “Company”) today announced the pricing of its initial public offering of 10,000,000 units at a price of $10.00 per unit. The...
-
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
-
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with...